Ultragenyx Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Ultragenyx Pharmaceutical has a total shareholder equity of $353.8M and total debt of $878.4M, which brings its debt-to-equity ratio to 248.3%. Its total assets and total liabilities are $1.5B and $1.2B respectively.
Key information
248.3%
Debt to equity ratio
US$878.42m
Debt
| Interest coverage ratio | n/a |
| Cash | US$607.51m |
| Equity | US$353.83m |
| Total liabilities | US$1.18b |
| Total assets | US$1.54b |
Recent financial health updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01Recent updates
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
Nov 12Ultragenyx: Excellent Company, Lackluster Stock
Nov 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Financial Position Analysis
Short Term Liabilities: RARE's short term assets ($799.6M) exceed its short term liabilities ($285.0M).
Long Term Liabilities: RARE's short term assets ($799.6M) do not cover its long term liabilities ($899.5M).
Debt to Equity History and Analysis
Debt Level: RARE's net debt to equity ratio (76.6%) is considered high.
Reducing Debt: RARE's debt to equity ratio has increased from 0% to 248.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RARE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RARE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.